Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer

Table 4 The efficacy of subsequent endocrine therapy for advanced breast cancer who have failed to respond to non–steroidal aromatase inhibitor

Author; Journal, year (Trial name)	Line	Design	n	ORR (%)	CBR (%)
Lϕnning; J Clin Oncol, 2000 [9]	2nd ~ 4th	nsAI → EXE	105	4.8	20.0
Iaffaioli; Br J Cancer, 2005 [10]	2nd ~ 3rd	ANA → EXE	50	8.0	44.0
Steele; Breast, 2005 [4]	2nd~ > 4th	nsAI → EXE	114	5.0	46.0
Thürlimann; Eur J Cancer, 2003 [13]	2nd	ANA → TAM	119	10.1	48.7
Chia; J Clin Oncol, 2008 (EFECT) [12]	2nd~ > 4th	nsAI → FUL loading dose	270	7.4	32.2
Chia; J Clin Oncol, 2008 (EFECT) [12]	2nd~ > 4th	nsAI → EXE	270	6.7	31.5
Yamamoto; Breast Cancer, 2010 (Hi-FAIR) [8]	2nd~ > 4th	AIs → TOR120	80	15.0	45.0
Di Leo; J Clin Oncol, 2010 [14]	2nd	AI or SERM → FUL500	362	9.1	45.6
Di Leo; J Clin Oncol, 2010 [14]	2nd	AI or SERM → FUL250	374	10.2	39.6
Bachelot T: J Clin Oncol. 2012 (TAMRAD) [17]	2nd~ > 4th	nsAI → TAM	57	13.0	42.1
Bachelot T: J Clin Oncol. 2012 (TAMRAD) [17]	2nd~ > 4th	nsAI → TAM + RAD001	54	14.0	61.1
Baselga; N Engl J Med, 2012 (Bolero2) [16]	2nd ~ 4th	nsAI → EXE	239	0.4	18.0
Baselga; N Engl J Med, 2012 (Bolero2) [16]	2nd ~ 4th	nsAI → EXE + RAD001	484	9.5	33.4

nsAI: non-steroidal aromatase inhibitor, EXE: exemestane, ANA: anastrozle, TAM: tamoxifen, FUL: fulvestrant, SERM: selective estrogen receptor modulator.

ISSN: 1471-2407